Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.2% – What’s Next?

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) traded down 6.2% during trading on Friday . The stock traded as low as $4.79 and last traded at $4.7760. 1,137,663 shares traded hands during trading, a decline of 58% from the average session volume of 2,722,284 shares. The stock had previously closed at $5.09.

Analyst Ratings Changes

A number of equities research analysts have recently commented on TSHA shares. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Citizens Jmp boosted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Taysha Gene Therapies presently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Taysha Gene Therapies Stock Performance

The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $1.28 billion, a PE ratio of -14.17 and a beta of 1.02. The firm’s fifty day moving average price is $5.06 and its 200 day moving average price is $4.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 260,047 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the transaction, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 570,172 shares of company stock valued at $2,637,906 in the last 90 days. Corporate insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC boosted its holdings in Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after purchasing an additional 82,545 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Taysha Gene Therapies by 7.0% during the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock worth $286,000 after acquiring an additional 13,383 shares in the last quarter. Chicago Partners Investment Group LLC lifted its holdings in Taysha Gene Therapies by 40.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 163,766 shares of the company’s stock worth $378,000 after purchasing an additional 47,201 shares during the last quarter. Ethic Inc. acquired a new position in Taysha Gene Therapies during the second quarter valued at approximately $67,000. Finally, Tybourne Capital Management HK Ltd. lifted its stake in shares of Taysha Gene Therapies by 10.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after buying an additional 395,000 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.